Table 2B.
Estimated incidence of cardiovascular adverse events associated with immune checkpoint inhibitor therapy based on a safety meta-analysis (35, 36).
Cardiovascular Adverse Event | Summary Incidence (95% CI) |
---|---|
Myocarditis | 0.3% (0.2 – 0.5%) |
Pericarditis | 0.8% (0.6 – 1.1%) |
Arrhythmias | 1% |
Heart Failure | 0.9% (0.7 – 1.1%) |
Myocardial Infarction | 0.7% (0.6 – 0.9%) |
Ischemic Stroke | 0.9% (0.7% – 1.1%) |
Venous Thromboembolism | 12.9% |
Dyslipidemia | 1.9% (0.7 – 5.4%) |